NCT06034925View on ClinicalTrials.gov

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

August 30, 2025

Conditions

Transplant ComplicationCMV

Interventions

DRUG

Maribavir

maribavir 400mg twice daily

DRUG

Valganciclovir

valganciclovir 900mg once daily

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

Medical University of South Carolina

OTHER